Syndax Pharmaceuticals (SNDX) Cash from Operations Growth (5y) (2020 - 2026)
Syndax Pharmaceuticals (SNDX) Cash from Operations Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | Syndax Pharmaceuticals | 1.85 Bn | 1.50 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.38% |
| Dec 31, 2025 | -34.77% |
| Sep 30, 2025 | -30.98% |
| Jun 30, 2025 | -32.61% |
| Mar 31, 2025 | -42.98% |
| Dec 31, 2024 | -35.15% |
| Sep 30, 2024 | -48.85% |
| Jun 30, 2024 | -41.74% |
| Mar 31, 2024 | -37.77% |
| Dec 31, 2023 | -22.41% |
| Sep 30, 2023 | -19.31% |
| Jun 30, 2023 | -18.48% |
| Mar 31, 2023 | -14.57% |
| Dec 31, 2022 | -12.47% |
| Sep 30, 2022 | -22.90% |
| Jun 30, 2022 | -27.85% |
| Mar 31, 2022 | -27.05% |
| Dec 31, 2021 | 63.46% |
| Sep 30, 2021 | -16.85% |
| Jun 30, 2021 | -28.40% |